Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.65 USD | +3.10% | +1.73% | -9.60% |
Apr. 02 | Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer | CI |
Apr. 02 | Voyager Therapeutics, Inc. Announces CFO Changes | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.72% | 403M | D+ | ||
+1.71% | 42.59B | B | ||
+7.89% | 40.65B | B- | ||
+49.22% | 40.57B | A | ||
-12.36% | 26.77B | C | ||
+9.20% | 24.81B | B- | ||
-24.68% | 18.17B | B | ||
+28.26% | 12.05B | C+ | ||
-3.35% | 11.7B | C+ | ||
+6.87% | 11.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VYGR Stock
- Ratings Voyager Therapeutics, Inc.